Akero Therapeutics Inc., a clinical-stage company focused on developing treatments for serious metabolic diseases, has announced the publication of results from the Phase 2b HARMONY clinical trial in The Lancet. The study evaluated the efficacy of efruxifermin $(EFX)$ in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) over a 96-week period. The results indicate that 49% of participants receiving 50mg EFX showed at least one stage improvement in liver fibrosis without worsening MASH, compared to 19% for the placebo group (p=0.0030). These findings were supported by digital pathology and improvements in non-invasive markers such as liver stiffness and ELF score. The trial was a multicenter, randomized, double-blind, placebo-controlled study, which confirmed the potential of EFX to address liver fibrosis and metabolic health in affected individuals.